BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36012384)

  • 1.
    Pizzuto DA; Triumbari EKA; Morland D; Boldrini L; Gatta R; Treglia G; Bientinesi R; De Summa M; De Risi M; Caldarella C; Scarciglia E; Totaro A; Annunziata S
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of radiomic analysis of [
    Marturano F; Guglielmo P; Bettinelli A; Zattoni F; Novara G; Zorz A; Sepulcri M; Gregianin M; Paiusco M; Evangelista L
    Eur Radiol; 2023 Oct; 33(10):7199-7208. PubMed ID: 37079030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung uptake of fluorine-18 fluoroethyl-choline PET-CT in patients with prostate cancer.
    Pizzuto DA; Annunziata S; Ieria FP; Caldarella C; Isgrò MA; Lanni V; Bencivenga G; Rufini V; Giordano A
    Q J Nucl Med Mol Imaging; 2019 Dec; 63(4):387-393. PubMed ID: 29345442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic performance of
    Samper Ots P; Luis Cardo A; Vallejo Ocaña C; Cabeza Rodríguez MA; Glaria Enríquez LA; Couselo Paniagua ML; Olivera Vegas J
    Clin Transl Oncol; 2019 Jun; 21(6):766-773. PubMed ID: 30448957
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligometastatic recurrent prostate cancer detects by fluorine-18-choline positron emission tomography/computed tomography in patients with prostate-specific antigen levels of up to 5 ng/ml.
    Evangelista L; Cuppari L; Guttilla A; Gardi M; Agostini A; Ruggera L; Basso U; Saladini G
    Nucl Med Commun; 2018 Mar; 39(3):260-267. PubMed ID: 29381584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of
    Jiménez Londoño GA; García Vicente AM; Amo-Salas M; Fúnez Mayorga F; López Guerrero MA; Talavera Rubio MP; Gutierrez Martin P; González García B; de la Torre Pérez JA; Soriano Castrejón ÁM
    Rev Esp Med Nucl Imagen Mol; 2017; 36(4):241-246. PubMed ID: 28330596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of (18)F-fluorocholine positron-emission tomography/computed tomography (PET/CT) in biochemical relapse of prostate cancer after radical treatment: results of a multicentre study.
    Rodado-Marina S; Coronado-Poggio M; García-Vicente AM; García-Garzón JR; Alonso-Farto JC; de la Jara AC; Maldonado-Suárez A; Rodríguez-Fernández A
    BJU Int; 2015 Jun; 115(6):874-83. PubMed ID: 25307619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?
    Castellucci P; Fuccio C; Rubello D; Schiavina R; Santi I; Nanni C; Allegri V; Montini GC; Ambrosini V; Boschi S; Martorana G; Marzola MC; Fanti S
    Eur J Nucl Med Mol Imaging; 2011 Jan; 38(1):55-63. PubMed ID: 20848281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of fluorine-18-fluoromethylcholine PET/CT to prostate-specific antigen over different plasma levels: a retrospective study in a cohort of 192 patients with prostate cancer.
    Giovacchini G; Giovannini E; Borsò E; Lazzeri P; Riondato M; Leoncini R; Duce V; Conti E; Picchio M; Ciarmiello A
    Nucl Med Commun; 2019 Mar; 40(3):258-263. PubMed ID: 30507748
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual time point imaging of staging PSMA PET/CT quantification; spread and radiomic analyses.
    Aksu A; Vural Topuz Ö; Yılmaz G; Çapa Kaya G; Yılmaz B
    Ann Nucl Med; 2022 Mar; 36(3):310-318. PubMed ID: 34988888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gleason score at diagnosis predicts the rate of detection of 18F-choline PET/CT performed when biochemical evidence indicates recurrence of prostate cancer: experience with 1,000 patients.
    Cimitan M; Evangelista L; Hodolič M; Mariani G; Baseric T; Bodanza V; Saladini G; Volterrani D; Cervino AR; Gregianin M; Puccini G; Guidoccio F; Fettich J; Borsatti E
    J Nucl Med; 2015 Feb; 56(2):209-15. PubMed ID: 25552670
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical parameters and nomograms for predicting lymph node metastasis detected with
    Onal C; Ozyigit G; Oymak E; Guler OC; Hurmuz P; Tilki B; Reyhan M; Tuncel M; Akyol F
    Prostate; 2021 Jul; 81(10):648-656. PubMed ID: 33949694
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
    Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?
    Chondrogiannis S; Marzola MC; Ferretti A; Grassetto G; Maffione AM; Rampin L; Fanti S; Giammarile F; Rubello D
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1293-300. PubMed ID: 24566948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 18F-choline PET/computed tomography and clinical parameters in the detection of significant prostate cancer in patients with increased prostate-specific antigen levels and previous negative biopsies.
    Jiménez Londoño GA; García Vicente AM; Noriega Álvarez E; Pena Pardo FJ; Amo-Salas M; López Guerrero MA; Fúnez Mayorga F; Soriano Castrejón ÁM
    Nucl Med Commun; 2020 Jul; 41(7):674-681. PubMed ID: 32404644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment and prospective validation of an SUV
    Jiao J; Kang F; Zhang J; Quan Z; Wen W; Zhao X; Ma S; Wu P; Yang F; Guo W; Yang X; Yuan J; Shi Y; Wang J; Qin W
    Theranostics; 2021; 11(17):8396-8411. PubMed ID: 34373749
    [No Abstract]   [Full Text] [Related]  

  • 19. Utility of radiomic zones for risk classification and clinical outcome predictions using supervised machine learning during simultaneous
    Tu SJ; Tran VT; Teo JM; Chong WC; Tseng JR
    Med Phys; 2021 Sep; 48(9):5192-5201. PubMed ID: 34214211
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis.
    Lin CY; Lee MT; Lin CL; Kao CH
    Clin Nucl Med; 2019 May; 44(5):365-376. PubMed ID: 30888999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.